{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:54:21Z","timestamp":1776048861929,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AIRC-CRF Multi-user Equipment Program 2016","award":["19515"],"award-info":[{"award-number":["19515"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Pheochromocytoma (Pheo) and paraganglioma (PGL) are rare tumors, mostly resulting from pathogenic variants of predisposing genes, with a genetic contribution that now stands at around 70%. Germline variants account for approximately 40%, while the remaining 30% is attributable to somatic variants. Objective: This study aimed to describe a new PHD2 (EGLN1) variant in a patient affected by metastatic Pheo and chronic myeloid leukemia (CML) without polycythemia and to emphasize the need to adopt a comprehensive next-generation sequencing (NGS) panel. Methods: Genetic analysis was carried out by NGS. This analysis was initially performed using a panel of genes known for tumor predisposition (EGLN1, EPAS1, FH, KIF1B\u03b2, MAX, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, and VHL), followed initially by SNP-CGH array, to exclude the presence of the pathogenic Copy Number Variants (CNVs) and the loss of heterozygosity (LOH) and subsequently by whole exome sequencing (WES) comparative sequence analysis of the DNA extracted from tumor fragments and peripheral blood. Results: We found a novel germline PHD2 (EGLN1) gene variant, c.153G&gt;A, p.W51*, in a patient affected by metastatic Pheo and chronic myeloid leukemia (CML) in the absence of polycythemia. Conclusions: According to the latest guidelines, it is mandatory to perform genetic analysis in all Pheo\/PGL cases regardless of phenotype. In patients with metastatic disease and no evidence of polycythemia, we propose testing for PHD2 (EGLN1) gene variants. A possible correlation between PHD2 (EGLN1) pathogenic variants and CML clinical course should be considered.<\/jats:p>","DOI":"10.3390\/medicina58081113","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T22:53:30Z","timestamp":1660776810000},"page":"1113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-8412","authenticated-orcid":false,"given":"Aldesia","family":"Provenzano","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-0604","authenticated-orcid":false,"given":"Massimiliano","family":"Chetta","sequence":"additional","affiliation":[{"name":"Medical Genetics, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Cardarelli, Padiglione, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-5526","authenticated-orcid":false,"given":"Giuseppina","family":"De Filpo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cantini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-8404","authenticated-orcid":false,"given":"Andrea","family":"La Barbera","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2614-944X","authenticated-orcid":false,"given":"Gabriella","family":"Nesi","sequence":"additional","affiliation":[{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"Department of Health Sciences, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Santi","sequence":"additional","affiliation":[{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"Department of Health Sciences, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-2252","authenticated-orcid":false,"given":"Serena","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3826-2714","authenticated-orcid":false,"given":"Elena","family":"Rapizzi","sequence":"additional","affiliation":[{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-064X","authenticated-orcid":false,"given":"Michaela","family":"Luconi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-4221","authenticated-orcid":false,"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"},{"name":"Endocrinology Unit, Azienda Ospedaliera-Universitaria Careggi, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-9857","authenticated-orcid":false,"given":"Massimo","family":"Mannelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonino","family":"Ercolino","sequence":"additional","affiliation":[{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"},{"name":"Endocrinology Unit, Azienda Ospedaliera-Universitaria Careggi, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-8108","authenticated-orcid":false,"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50139 Florence, Italy"},{"name":"Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy"},{"name":"European Network for the Study of Adrenal Tumors (ENS@T) Center of Excellence, 50139 Florence, Italy"},{"name":"Endocrinology Unit, Azienda Ospedaliera-Universitaria Careggi, 50139 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Majewska, A., Budny, B., Ziemnicka, K., Rucha\u0142a, M., and Wierzbicka, M. (2020). Head and Neck Paragangliomas\u2014A Genetic Overview. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207669"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123I-MIBG scintigraphy on clinical decision-making in pheochromocytoma and paraganglioma","volume":"104","author":"Rao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Hicks","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients with Metastatic Pheochromocytoma or Sympathetic Paraganglioma","volume":"268","author":"Zhou","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1210\/jc.2013-1907","article-title":"One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma","volume":"98","author":"Hescot","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kolasinska-\u0106wik\u0142a, A., P\u0119czkowska, M., \u0106wik\u0142a, J.B., Micha\u0142owska, I., Pa\u0142ucki, J.M., Bodei, L., Lewczuk-My\u015blicka, A., and Januszewicz, A. (2019). A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070952"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"Mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr. -Relat. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","article-title":"External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma","volume":"3","author":"Breen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: The SNIPP trial","volume":"120","author":"Ezzat","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide Is a Potential Therapeutic Tool for Patients with Metastatic Pheochromocytoma\/Paraganglioma-Case Report and Review of the Literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Subbiah, V., Stephen, B., Ma, J., Milton, D., Xu, M., Zarifa, A., Akhmedzhanov, F.O., Tsimberidou, A., and Habra, M.A. (2020). Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers, 12.","DOI":"10.3390\/cancers12082307"},{"key":"ref_16","first-page":"101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract","volume":"34","author":"Buffet","year":"2020","journal-title":"Res. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1093\/hmg\/ddaa201","article-title":"Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: Implications for precision medicine","volume":"29","author":"Casey","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP14481.RA","article-title":"Pheochromocytoma and paraganglioma","volume":"21","author":"Pacak","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","article-title":"Genomic Landscape of Pheochromocytoma and Paraganglioma","volume":"4","author":"Jochmanova","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2010","journal-title":"Endocr. -Relat. Cancer"},{"key":"ref_21","first-page":"625","article-title":"Genetics of paragangliomas and pheochromocytomas","volume":"28","author":"Favier","year":"2012","journal-title":"Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Berends, A.M.A., Eisenhofer, G., Fishbein, L., Horst-Schrivers, A.N.A.V., Kema, I.P., Links, T.P., Lenders, J.W.M., and Kerstens, M.N. (2019). Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. Cancers, 11.","DOI":"10.3390\/cancers11081121"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1530\/EC-20-0472","article-title":"Pheochromocytoma\/paraganglioma preclinical models: Which to use and why?","volume":"9","author":"Martinelli","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"The NGS in PPGL (NGSnPPGL) Study Group, Toledo, R., Burnichon, N., Cascon, A., Benn, D.E., Bayley, J.-P., Welander, J., Tops, C.M., Firth, H., and Dwight, T. (2017). Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat. Rev. Endocrinol., 13, 233\u2013247.","DOI":"10.1038\/nrendo.2016.185"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0959-437X(00)00193-3","article-title":"Activation of the HIF pathway in cancer","volume":"11","author":"Maxwell","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/sj.bjc.6603675","article-title":"Target gene selectivity of hypoxia-inducible factor-\u03b1 in renal cancer cells is conveyed by post-DNA-binding mechanisms","volume":"96","author":"Lau","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-\u03b1 prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1365-2826.2008.01755.x","article-title":"Analysis of Selected Genes in Neuroendocrine Tumours: Insulinomas and Phaeochromocytomas","volume":"20","year":"2008","journal-title":"J. Neuroendocr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","article-title":"Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing","volume":"98","author":"Crona","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2007-04-084434","article-title":"A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove","volume":"110","author":"Percy","year":"2007","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E908","DOI":"10.1210\/jc.2013-1217","article-title":"First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome","volume":"98","author":"Yang","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J. Mol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"W174","DOI":"10.1093\/nar\/gkv342","article-title":"I-TASSER server: New development for protein structure and function predictions","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-0134(1997)1+<226::AID-PROT31>3.0.CO;2-O","article-title":"Evaluation of GRAMM low-resolution docking methodology on the hemagglutinin-antibody complex","volume":"29","author":"Vakser","year":"1997","journal-title":"Proteins"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1073\/pnas.96.15.8477","article-title":"A systematic study of low-resolution recognition in protein\u2014protein complexes","volume":"96","author":"Vakser","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/ERC-11-0263","article-title":"Mitochondrial function and content in pheochromocytoma\/paraganglioma of succinate dehydrogenase mutation carriers","volume":"19","author":"Rapizzi","year":"2012","journal-title":"Endocr. -Relat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/ERC-14-0479","article-title":"Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function","volume":"22","author":"Rapizzi","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2018-01717","article-title":"Fascin-1 Is a Novel Prognostic Biomarker Associated with Tumor Invasiveness in Adrenocortical Carcinoma","volume":"104","author":"Poli","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cantini, G., Fei, L., Canu, L., Lazzeri, E., Sottili, M., Francalanci, M., Angelotti, M.L., De Filpo, G., Ercolino, T., and Gelmini, S. (2021). Stimulated Expression of CXCL12 in Adrenocortical Carcinoma by the PPARgamma Ligand Rosiglitazone Impairs Cancer Progression. J. Pers. Med., 11.","DOI":"10.3390\/jpm11111097"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/humu.24051","article-title":"AutoPVS1: An automatic classification tool for PVS1 interpretation of null variants","volume":"41","author":"Xiang","year":"2020","journal-title":"Hum. Mutat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bcmd.2007.07.017","article-title":"Disturbance in the HIF-1\u03b1 pathway associated with erythrocytosis: Further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene","volume":"40","author":"Moradkhani","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_47","first-page":"6373706","article-title":"Erythrocytosis due to PHD2 Mutations: A Review of Clinical Presentation, Diagnosis, and Genetics","volume":"2016","author":"Wilson","year":"2016","journal-title":"Case Rep. Hematol."},{"key":"ref_48","first-page":"S251","article-title":"HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors","volume":"63","author":"Zelinka","year":"2014","journal-title":"Physiol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/HP.S54455","article-title":"The role of PHD2 mutations in the pathogenesis of erythrocytosis","volume":"2","author":"Gardie","year":"2014","journal-title":"Hypoxia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/cge.13055","article-title":"The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers","volume":"93","author":"Rijken","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2011.044644","article-title":"Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia","volume":"97","author":"Ladroue","year":"2011","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18928","DOI":"10.1038\/srep18928","article-title":"Oxidative Dimerization of PHD2 is Responsible for its Inactivation and Contributes to Metabolic Reprogramming via HIF-1\u03b1 Activation","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1\u03b1, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","article-title":"Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations","volume":"20","author":"Giuntoli","year":"2006","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3324\/haematol.2010.029082","article-title":"Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate","volume":"96","author":"Giuntoli","year":"2011","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1\u03b1-induced metabolic reprograming","volume":"29","author":"Zhao","year":"2010","journal-title":"Oncogene"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:10:57Z","timestamp":1760141457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/8\/1113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["medicina58081113"],"URL":"https:\/\/doi.org\/10.3390\/medicina58081113","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}